Search Results for: uploads
Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Stage 2 Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
DEL MAR Stage 2 Study Meets Primary Endpoint of Vision Non-Inferiority to Anti-VEGF with 12 Week Durability in a Mostly Chronic Anti-VEGF DME Population Download the PDF SAN JUAN CAPISTRANO, CA — August 9, 2017 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat neovascular retinal diseases, today […]
Allegro Ophthalmics Secures $10.7 Million in Private Financing
Download the PDF SAN JUAN CAPISTRANO, Calif. — July 24, 2017 — Allegro Ophthalmics, LLC today announced the completion of a private round of equity financing for $10.7 million. With this infusion of capital, the company is strongly positioned to reach future corporate milestones. Allegro is a biotechnology company focused on the development of novel […]
Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs
Download the PDF SAN JUAN CAPISTRANO — March 7, 2017 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, today announced that Melvin Sarayba, MD, has joined the company as vice president of clinical affairs. In his new role, Dr. Sarayba is responsible for Allegro’s US […]
Allegro Ophthalmics Completes Enrollment in DEL MAR Phase 2b, Stage 2 Clinical Trial of Luminate® for the Treatment of Diabetic Macular Edema
Download the PDF SAN JUAN CAPISTRANO — December 15, 2016 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, today announced completion of enrollment in the second stage of its DEL MAR trial that is evaluating the safety and efficacy of Luminate® in combination and as […]
William J. Link, PhD, Joins Allegro Ophthalmics’ Board of Directors
Download the PDF SAN JUAN CAPISTRANO, CA —NOVEMBER 21, 2016 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, today announced that William J. Link, PhD, has been elected to Allegro’s board of directors. Dr. Link is co-founder and a managing director of Versant Ventures, a […]
Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
Download the PDF DEL MAR Study Meets Primary and Secondary Endpoints Demonstrating Equivalence to Anti-VEGF with Half the Number of Injections SAN JUAN CAPISTRANO, CA — October 13, 2016 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, today announced that the DEL MAR Phase 2b […]
Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate® for Non-Proliferative Diabetic Retinopathy
Download the PDF SAN JUAN CAPISTRANO, CA — October 3, 2016 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of therapies to treat vitreoretinal diseases, today announced completion of enrollment in its PACIFIC Phase 2b clinical trial that is evaluating the safety and efficacy of Luminate® (ALG-1001) in inducing posterior vitreous detachment […]
Ron Kurtz, MD, and Mark Livingston Join Allegro Ophthalmics’ Board of Directors
Download the PDF — Ron Kurtz, MD, and Mark Livingston Join Allegro Ophthalmics’ Board of Directors SAN JUAN CAPISTRANO, CA —AUGUST 1, 2016 — Allegro Ophthalmics, LLC, a late stage biotechnology company focused on the development of therapies to treat vitreoretinal diseases, today announced that Ron Kurtz, MD, president and CEO of Calhoun Vision, and Mark […]
Allegro Ophthalmics Announces Two Executive Promotions
Download the PDF — Vicken Karageozian, MD, Named President and Chief Medical Officer — John Park, PhD, Named Chief Scientific Officer and Vice President of Manufacturing Development SAN JUAN CAPISTRANO, CA — MARCH 15, 2016 — Allegro Ophthalmics, LLC, a late stage biotechnology company focused on the development of therapies to treat vitreoretinal diseases, today […]
